Study of TCB008 for leukemia that has returned or not responded to treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You weigh at least 50 kg (about 110 pounds).
- You have been diagnosed with AML or MDS/AML that has returned or not responded to at least one prior treatment.
- You are able to care for yourself (up to bedridden less than 50% of the time).
- Your heart, liver, and kidneys are functioning well enough, as determined by tests.
- You have not had a stem cell transplant or CAR-T therapy within the last 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.